Update
$ADC Therapeutics(ADCT.US$ ADC Therapeutics Announces Initial Data From Investigator-Initiated Phase 2 Clinical Trial of Zynlonta® in Patients With Relapsed/Refractory Marginal Zone Lymphoma ADC Therapeutics SA - Zynlonta Was Generally Well-Tolerated and Safety Was Consistent With Known Profile
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
